126 related articles for article (PubMed ID: 35510369)
1. Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2.
Ameratunga R; Woon ST; Steele R; Lehnert K; Leung E; Brooks AES
Expert Rev Clin Immunol; 2022 Jun; 18(6):557-565. PubMed ID: 35510369
[TBL] [Abstract][Full Text] [Related]
2. The (apparent) antibody paradox in COVID-19.
Ameratunga R; Woon ST; Lea E; Steele R; Lehnert K; Leung E; Brooks AES
Expert Rev Clin Immunol; 2022 Apr; 18(4):335-345. PubMed ID: 35184669
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 the ASIA virus (Autoimmune/autoinflammatory Syndrome Induced by Adjuvants), the risk of infertility and vaccine hesitancy.
Ameratunga R
Expert Rev Vaccines; 2022 Sep; 21(9):1177-1184. PubMed ID: 35695410
[TBL] [Abstract][Full Text] [Related]
4. A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants.
Wang CY; Hwang KP; Kuo HK; Peng WJ; Shen YH; Kuo BS; Huang JH; Liu H; Ho YH; Lin F; Ding S; Liu Z; Wu HT; Huang CT; Lee YJ; Liu MC; Yang YC; Lu PL; Tsai HC; Lee CH; Shi ZY; Liu CE; Liao CH; Chang FY; Chen HC; Wang FD; Hou KL; Cheng J; Wang MS; Yang YT; Chiu HC; Jiang MH; Shih HY; Shen HY; Chang PY; Lan YR; Chen CT; Lin YL; Liang JJ; Liao CC; Chou YC; Morris MK; Hanson CV; Guirakhoo F; Hellerstein M; Yu HJ; King CC; Kemp T; Heppner DG; Monath TP
J Clin Invest; 2022 May; 132(10):. PubMed ID: 35316221
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2022; 13():840126. PubMed ID: 35359967
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Omicron variant: recent progress and future perspectives.
Fan Y; Li X; Zhang L; Wan S; Zhang L; Zhou F
Signal Transduct Target Ther; 2022 Apr; 7(1):141. PubMed ID: 35484110
[TBL] [Abstract][Full Text] [Related]
8. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
9. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
11. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
12. Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19.
Ameratunga R; Longhurst H; Steele R; Lehnert K; Leung E; Brooks AES; Woon ST
J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3575-3583. PubMed ID: 34182162
[TBL] [Abstract][Full Text] [Related]
13. Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2.
Bormann M; van de Sand L; Witzke O; Krawczyk A
Klin Monbl Augenheilkd; 2021 May; 238(5):569-578. PubMed ID: 34020485
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
He X; Zeng XX
Drug Des Devel Ther; 2022; 16():951-972. PubMed ID: 35386853
[TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
[TBL] [Abstract][Full Text] [Related]
16. Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant.
Villas-Boas LS; Paula AV; Silva ARD; Paiao HGO; Tozetto-Mendoza TR; Manuli ER; Leal FE; Ferraz ABC; Sabino EC; Bierrenbach AL; Witkin SS; Mendes-Correa MC
Clinics (Sao Paulo); 2022; 77():100068. PubMed ID: 35767900
[TBL] [Abstract][Full Text] [Related]
17. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.
Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803
[TBL] [Abstract][Full Text] [Related]
18. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
[TBL] [Abstract][Full Text] [Related]
19. Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma.
Yu D; Li YF; Liang H; Wu JZ; Hu Y; Peng Y; Li TJ; Hou JF; Huang WJ; Guan LD; Han R; Xing YT; Zhang Y; Liu J; Feng L; Li CY; Liang XL; Ding YL; Zhou ZJ; Ji DM; Wang FF; Yu JH; Deng K; Xia DM; Dong DM; Hu HR; Liu YJ; Fu DX; He YL; Zhou DB; Yang HC; Jia R; Ke CW; Du T; Xie Y; Zhou R; Li CS; Wang ML; Yang XM
Adv Sci (Weinh); 2022 May; 9(14):e2104333. PubMed ID: 35403837
[TBL] [Abstract][Full Text] [Related]
20. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
Lindholm PF; Ramsey G; Kwaan HC
Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
